|
|
Volumn 9, Issue SUPPL. 1, 2009, Pages
|
|
The basics of preclinical drug development for neurodegenerative disease indications
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
CENTRAL NERVOUS SYSTEM AGENTS;
ALZHEIMER DISEASE;
AMYOTROPHIC LATERAL SCLEROSIS;
ANALYTIC METHOD;
ARTICLE;
BLOOD BRAIN BARRIER;
CLINICAL RESEARCH;
CONTINUOUS INFUSION;
DEGENERATIVE DISEASE;
DOCUMENTATION;
DRUG ABSORPTION;
DRUG ADMINISTRATION ROUTE;
DRUG APPROVAL;
DRUG BLOOD LEVEL;
DRUG CLEARANCE;
DRUG DESIGN;
DRUG DISTRIBUTION;
DRUG EXCRETION;
DRUG FORMULATION;
DRUG INDICATION;
DRUG INDUSTRY;
DRUG METABOLISM;
DRUG SAFETY;
DRUG SCREENING;
FOOD AND DRUG ADMINISTRATION;
FUNDING;
GOOD MANUFACTURING PRACTICE;
HUMAN;
HUNTINGTON CHOREA;
MAXIMUM PLASMA CONCENTRATION;
MULTIPLE SCLEROSIS;
NONHUMAN;
PARKINSON DISEASE;
TIME TO MAXIMUM PLASMA CONCENTRATION;
TOXICITY TESTING;
TOXICOKINETICS;
ANIMAL;
CHEMISTRY;
GOVERNMENT REGULATION;
REVIEW;
TOXICOLOGY;
UNITED STATES;
ANIMALS;
CENTRAL NERVOUS SYSTEM AGENTS;
CHEMISTRY, PHARMACEUTICAL;
DRUG DESIGN;
DRUG EVALUATION, PRECLINICAL;
GOVERNMENT REGULATION;
HUMANS;
NEURODEGENERATIVE DISEASES;
TOXICOLOGY;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
|
EID: 67650088426
PISSN: None
EISSN: 14712377
Source Type: Journal
DOI: 10.1186/1471-2377-9-S1-S2 Document Type: Article |
|
Times cited : (92)
|
|
References (16)
|
